Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

Belrestotug (EOS-448/GSKFF28849A): IgG1 anti-TIGIT monoclonal antibody in development for the first-line treatment of locally advanced or metastatic PD-L1-high non-small cell lung cancer (NSCLC ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

Partner AstraZeneca’s (AZN) anti-PD-1/TIGIT bispecific antibody rilvegostomig incorporates Compugen technology and is in five Phase 3 trials in lung and biliary tract cancers, Oppenheimer points ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response ...